Welcome to pay attention to the "Investment Strategy" Baijia account to learn more about the new trends in the industry
1.Hengrui Pharmaceutical.
Self-developed, Tican toxoid ADC platform.
Main targets: HER2, TROP2, CLAUDIN182、cd79b、her3、nectin-4、c-met
The new generation of site-directed conjugation technology, new cytotoxic payload and new linker, new dual antibody ADC project, and new conjugation technology are applied in the field of antibody-photosensitizer conjugate (APC) and antibody-radionuclide conjugate (ARC).
2.Remegen.
Self-developed, fully integrated ADC platform.
Main targets: HER2, mesothelin, C-met, Claudin182
Screening platform for ADC linker and load optimization, proprietary thiel-bridge coupling technology, payload and coupling process development, GMP synthesis of linkers, payloads and linker payloads, GMP production of DS and DP for ADC.
3.Columbote.
Self-developed, fully integrated ADC platform Optidc
Main targets: TROP2, HER2, CLAUDIN182
Bioinformatics-assisted antibody discovery workflows have been developed, and an extensive library of cytotoxic small molecules has been established to create reasonably stable hydrophilic linkers for selective cleavage in tumors. DAR with the ability to customize the ADC with a carbonate structure that releases the payload in the acidic tumor microenvironment.
4.Mabwell.
Self-developed, next-generation ADC fixed-point coupling technology platform IDDCTM
Main targets: Nectin-4, TROP2, B7-H3
A new generation of site-specific coupling process DarfinityTM, a site-specific coupling linker idConnectTM, a new topoisomerase load MTOXINTM, and a new release structure - LysonlyTM
5.Baili Tianheng.
Self-developed, full-chain integrated ADC drug R&D core technology platform.
Main targets: EGFR HER3, TROP2, HER2, CD33
Payload technology (AC linker technology, toxin technology, release technology), site-directed conjugation technology, ADC drug evaluation, screening, production technology, bispecific antibody ADC
6.Bio-Thera.
Self-developed, a new platform for ADC technology.
Main targets: FR, B7H3, HER2, TROP2, NECTIN-4
Toxic small molecule topoisomerase I inhibitors are conjugated to antibodies using cleavable linkers.
7.Lepu Biotech.
Introduction + self-development, the introduction of GlycoConnectTM and HydrAspaceTM self-developed new linker-payload platform.
Main targets: EGFR, HER2, CD20, TF, CLDN182
State-of-the-art coupling technology, optimized technology for precise control of the DAR, and a new linker-payload platform.
8.Innovent Biologics.
Introduced + self-developed, and cooperated with Synaffix to build an integrated ADC platform.
Main target: claudin182、her2、b7h3、trop2
World-leading ADC technology, self-developed TAA platform, differentiated linker-payload technology, and unique drug design.
9.Henlius.
Self-developed, HanjugatorTM
Main targets: EGFR, PD-L1
Novel toxin-linker and stable conjugation methods, development of toxin-linkers released by tumor microenvironment activation, exploration of multi-warhead ADCs, development of conditionally activated antibodies, and introduction of novel toxins or non-toxin payloads
10.Yilian Biotech.
Self-developed, Tmalin technology.
Main targets: HER3, DLL3
It has unique enzymatic digestion characteristics and tumor enrichment characteristics, and has the ability to dissolve cells outside the tumor microenvironment, and has extremely high systemic circulatory stability.
11.LaNova Pharmaceutical.
Self-developed, LX-ADCTM (next-generation ADC technology platform).
Main target: claudin182、gprc5d
ADC releases cytotoxicity against tumors and the microenvironment, novel target selection strategies, highly differentiated antibodies, and precisely designed linker + toxin payload combinations.
Popular